Mylan's found itself in another EpiPen scandal; only this time, the company may have overcharged the U.S. government.
Instead of paying a 23 percent rebate for a brand-name drug, Mylan has been paying a 13 percent rebate. That amounts to millions of dollars less to the government and taxpayers who need the drug.
At the same time, Mylan raised the price of a single pen to roughly $300 this year.
Mylan may have a harder time arguing EpiPens fall under the generic drug category, since during the height of its previous price scandal, the company said it would start selling a generic version of EpiPens for half-price.